You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

TRIUMEQ Has Few Significant DDIs1

Commonly used medications

Interactions

Oral contraceptives

No

H2-antagonists (including ranitidine, cimetidine)

No

Hepatitis C protease inhibitors (telaprevir, boceprevir, daclatasvir)

No

Prednisone

No

Rifabutin

No

Methadone

Dosing adjustment likely not needed for most patients, occasionally methadone re-titration may be required.

Metformin

A dose adjustment of metformin should be considered when starting and stopping co-administration of dolutegravir with metformin, to maintain glycaemic control.

In patients with moderate renal impairment a dose adjustment of metformin should be considered when co-administered with dolutegravir, because of the increased risk for lactic acidosis in patients with moderate renal impairment due to increased metformin concentration.

Multivitamins, calcium supplements, iron supplements

TRIUMEQ is recommended to be administered 2 hours before or 6 hours after taking these agents

Magnesium/aluminium-containing antacids

TRIUMEQ is recommended to be administered 2 hours before or 6 hours after taking these agents

Rifampicin, efavirenz, nevirapine, and tipranavir/r

Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with these agents, the use of TRIUMEQ is not recommended for patients taking these medicines

  • Co-administration with dofetilide is contraindicated1
  • Triumeq is a fixed-dose pill and should not be prescribed for patients requiring dose adjustments1
  • Since the recommended dose of dolutegravir is 50 mg twice daily when co-administered with carbamazepine, phenytoin, phenobarbital and St. John's wort, the use of Triumeq is not recommended for patients taking these medicines1
  • Co-administration with etravirine is not recommended unless patient is also receiving atazanavir/r, lopinavir/r or darunavir/r1
  • When possible, avoid chronic coadministration of Triumeq with medicinal products containing sorbitol or other osmotic acting poly-alcohols or monosaccharide alcohols (eg: xylitol, mannitol, lactitol, maltitol). Consider more frequent monitoring of HIV-1 viral load when chronic coadministration cannot be avoided1
  • Concomitant use of Triumeq with cladribine is not recommended.1
  • Dolutegravir is eliminated primarily by UGT1A1. Abacavir and lamivudine are not significantly metabolised by CYP enzymes.1

For further information, please see the Summary of Product Characteristics.

INI Metabolic Profiles

A visual exploration of the metabolic profiles of the HIV Integrase Inhibitors

Watch Video

DDIs=drug-drug interactions

Women of childbearing potential (WOCBP) should undergo pregnancy testing before initiation of dolutegravir. WOCBP who are taking dolutegravir should use effective contraception throughout treatment.1

Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

▼ These medicinal products are subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Trademarks are owned by or licensed to the ViiV Healthcare group of companies